Twist Bioscience Corporation
TWST
Ранг среди акций
#2097
Twist Bioscience Corporation operates as a leading synthetic biology firm,... Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Цена акции
$151.07
Рыночная капитализация
$9.95B
Изменение (1 день)
5.87%
Изменение (1 год)
352.44%
Страна
US
Торговля Twist Bioscience Corporation (TWST)
Категория
Healthcare
Выручка компании Twist Bioscience Corporation (TWST)
Выручка на Jun 2026 TTM: $431.80M
Согласно последним финансовым отчетам Twist Bioscience Corporation, текущая выручка компании (TTM) составляет $431.80M. В 2024 году компания получила выручку $312.97M больше, чем выручке в 2023 году, которая составила $245.11M. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Twist Bioscience Corporation с 2016 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $431.80M | 14.67% |
| 2025 | $376.57M | 20.32% |
| 2024 | $312.97M | 27.69% |
| 2023 | $245.11M | 20.41% |
| 2022 | $203.57M | 53.83% |
| 2021 | $132.33M | 46.87% |
| 2020 | $90.10M | 65.67% |
| 2019 | $54.39M | 113.89% |
| 2018 | $25.43M | 136.16% |
| 2017 | $10.77M | 374.53% |
| 2016 | $2.27M | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $46.34B | 10,630.94% |
US
|
|
| $25.11B | 5,714.52% |
US
|
|
| $2.71B | 526.93% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 1,607.28% |
US
|
